Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BPTH Bio-Path	$0.12	$0.16	$0.09 ▼ $3.39	$997K	-0.06	182,361 shs	18,611 shs
NMTR 9 Meters Biopharma		$0.00	$0.07 ▼ $6.56	$1.04M	1.36	315,915 shs	N/A
PTPI Petros Pharmaceuticals	$0.03 -1.8%	$0.03	$0.02 ▼ $16.25	$857K	1.56	4.98 million shs	260,246 shs
TFFP TFF Pharmaceuticals	$0.07	$0.06	$0.06 ▼ $3.23	$289K	N/A	N/A	N/A

Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BPTH Bio-Path	0.00%	-7.83%	-24.05%	-33.33%	-92.00%
NMTR 9 Meters Biopharma	0.00%	0.00%	-99.72%	-99.72%	-81.82%
PTPI Petros Pharmaceuticals	-4.51%	-10.13%	-7.09%	-29.49%	-99.68%
TFFP TFF Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	-96.88%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BPTH Bio-Path	0.8989 of 5 stars	0.0	5.0	0.0	0.0	0.6	0.0	1.3
NMTR 9 Meters Biopharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PTPI Petros Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TFFP TFF Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating	Consensus Price Target	% Upside from Current Price
BPTH Bio-Path	N/A	N/A	N/A
NMTR 9 Meters Biopharma	N/A	N/A	N/A
PTPI Petros Pharmaceuticals	N/A	N/A	N/A
TFFP TFF Pharmaceuticals	N/A	N/A	N/A

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BPTH Bio-Path	N/A	N/A	N/A	N/A	$0.71 per share	N/A
NMTR 9 Meters Biopharma	N/A	N/A	N/A	N/A	$0.19 per share	N/A
PTPI Petros Pharmaceuticals	$5.11M	0.17	N/A	N/A	$4.04 per share	0.01
TFFP TFF Pharmaceuticals	$730K	0.40	N/A	N/A	$4.04 per share	0.02

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BPTH Bio-Path	-$16.08M	N/A	0.00	N/A	N/A	N/A	-2,842.40%	-337.48%	N/A
NMTR 9 Meters Biopharma	-$43.77M	-$3.46	N/A	N/A	N/A	N/A	-584.97%	-159.45%	N/A
PTPI Petros Pharmaceuticals	-$8.16M	-$52.91	N/A	∞	N/A	N/A	-78.22%	-23.50%	N/A
TFFP TFF Pharmaceuticals	-$21.24M	-$6.44	N/A	∞	N/A	N/A	N/A	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BPTH Bio-Path	N/A	N/A	N/A	N/A	N/A
NMTR 9 Meters Biopharma	N/A	N/A	N/A	N/A	N/A
PTPI Petros Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TFFP TFF Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BPTH Bio-Path	N/A	0.86	0.86
NMTR 9 Meters Biopharma	N/A	0.59	0.59
PTPI Petros Pharmaceuticals	1.58	0.85	0.74
TFFP TFF Pharmaceuticals	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BPTH Bio-Path	5.74%
NMTR 9 Meters Biopharma	22.34%
PTPI Petros Pharmaceuticals	12.34%
TFFP TFF Pharmaceuticals	15.25%

Insider Ownership

Company	Insider Ownership
BPTH Bio-Path	0.72%
NMTR 9 Meters Biopharma	2.40%
PTPI Petros Pharmaceuticals	12.25%
TFFP TFF Pharmaceuticals	4.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BPTH Bio-Path	10	8.31 million	5.73 million	Optionable
NMTR 9 Meters Biopharma	20	14.34 million	13.99 million	No Data
PTPI Petros Pharmaceuticals	20	31.16 million	9.93 million	Not Optionable
TFFP TFF Pharmaceuticals	19	4.44 million	4.24 million	Optionable

TFFP, BPTH, NMTR, and PTPI Headlines

Recent News About These Companies

TFF Pharmaceuticals approves dissolution plan

March 8, 2025 | uk.investing.com

TFF Pharmaceuticals Announces Delisting from Nasdaq and Potential SEC Deregistration

February 6, 2025 | prnewswire.com

TFF Pharmaceuticals Inc (TFFP) Stock: A Deeper Look at Its True Potential

December 12, 2024 | bovnews.comB

The TFFP Stock Mystery: Why Did TFFP Plunge Today?

December 6, 2024 | bovnews.comB

TFF Pharmaceuticals Inc (TFFP) Stock: More Robust Than the Numbers Suggest?

November 23, 2024 | bovnews.comB

Stock Shock: The Unpredictable Rise and Fall of TFFP—What’s Driving the Drama?

November 20, 2024 | bovnews.comB

TFFP Unveiled: The Shocking Truth Behind TFF Pharmaceuticals Inc’s Latest Stock Movements

November 19, 2024 | bovnews.comB

U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.70%

November 15, 2024 | msn.com

TFF Pharmaceuticals (TFFP) Takes a Dark Turn: What’s Next for Investors?

November 15, 2024 | bovnews.comB

TFF Pharmaceuticals Shares Fall 66%; Company to Wind Down

November 14, 2024 | marketwatch.com

TFF Pharmaceuticals terminates employees, to wind down operations

November 14, 2024 | markets.businessinsider.com

TFF Pharmaceuticals to Dissolve and Liquidate Assets

November 14, 2024 | markets.businessinsider.com

TFF Pharmaceuticals, Inc. Announces Termination of Employees and Wind Down of Operations

November 14, 2024 | quiverquant.comQ

TFF Pharmaceuticals Announces It Will Wind Down Operations

November 14, 2024 | globenewswire.com

TFF Pharmaceuticals (NASDAQ:TFFP) Stock Quotes, Forecast and News Summary

October 9, 2024 | benzinga.com

TFF Pharmaceuticals (TFFP) Upgraded to Strong Buy: Here's Why

October 8, 2024 | zacks.com

TFF Pharmaceuticals, Inc.: TFF Pharmaceuticals' Technology Generates Superior Inhalational Dry Powder Formulations for Pulmonary Drug Delivery

September 26, 2024 | finanznachrichten.de

TFF Pharmaceuticals’ Technology Generates Superior Inhalational Dry Powder Formulations for Pulmonary Drug Delivery

September 26, 2024 | markets.businessinsider.com

Post-COVID Trends in Biopharma Contract Manufacturing

September 25, 2024 | contractpharma.comC

The Yadot Group to Acquire Experiential Agency Socials Dallas

September 16, 2024 | dallasinnovates.comD

New MarketBeat Followers Over Time

Media Sentiment Over Time

TFFP, BPTH, NMTR, and PTPI Company Descriptions

Bio-Path NASDAQ:BPTH

$0.12 0.00 (0.00%)

As of 08/22/2025 03:00 PM Eastern

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing BP1001-A that is in Phase I clinical trial for the treatment of solid tumors; Liposomal Bcl-2 (BP1002), which is in Phase I clinical trial for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003) for treating pancreatic cancer, non-small cell lung cancer, and AML. The company was founded in 2007 and is based in Bellaire, Texas.

9 Meters Biopharma NASDAQ:NMTR

9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders in North America. Its lead product candidate is Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 3 clinical trial to treat short bowel syndrome. The company is developing NM-136, a humanized monoclonal antibody for the treatment of obesity and obesity-related disorders; NM-102, a small molecule peptide to prevent antigens from trafficking into systemic circulation; and NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease. Its partnered product is Larazotide, an 8-amino acid peptide, which is in Phase 2 clinical trial for treatment of multi-system inflammatory syndrome. The company has licensing agreements with Amunix, MHS Care Innovation LLC, Alba Therapeutics Corporation, and EBRIS. 9 Meters Biopharma, Inc. is headquartered in Raleigh, North Carolina. On July 17, 2023, 9 Meters Biopharma, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the Eastern District of North Carolina.

Petros Pharmaceuticals NASDAQ:PTPI

$0.03 0.00 (-1.79%)

As of 08/22/2025 03:54 PM Eastern

Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health products, including vacuum erection devices, penile injections, PreBoost, VenoSeal, and urinary tract infection tests for the treatment of erectile dysfunction. Petros Pharmaceuticals, Inc. is based in New York, New York.

TFF Pharmaceuticals NASDAQ:TFFP

TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment and prophylaxis of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection. It also develops other dry powder products, such as Augmenta human derived monoclonal antibodies for the treatment of COVID-19 disease; and other vaccines. It has a license agreement with the University of Texas at Austin for the development of inhaled dry powder drugs. TFF Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Fort Worth, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time